

诺华：创新科技，承诺中华

Novartis: Innovative technology with commitment to China



[诺华中国公司]

● By Novartis China

诺华是全球领先的医药健康公司，总部位于瑞士巴塞尔。自创立以来，诺华一直保持创新的基因，开拓性地研发新型药物和治疗方法，惠及亿万患者。2007年以来，诺华每年将销售收入的16%以上投入研发，2014年集团研发投入达99亿美元，并为全球超过10亿患者提供医疗服务。

在中国，诺华始终秉承“承诺中华”的理念，立足于在中国的长期投入与发展。自1987年进入中国以来，诺华通过不断创新的产品和服务，致力于提高中国人民的健康水平和生活质量。同时，诺华还积极开展与中国各级政府以及医疗机构的多方面合作，支持中国政府打造一个更健康的中国。

诺华在中国开展顶级研发

随着环境及生活方式的改变，胃癌和肝癌等癌症发病率不断攀升，人口的老齡化趋势也让高血压、白内障等疾病日益影响着中国人的健康。

诺华投资10亿美元在上海设立集团三大研发中心之一的诺华（中国）生物医学研究中心，后者不仅参与全

Novartis is a leading pharmaceutical and healthcare company, headquartered in Basel, Switzerland. Since its inception, Novartis has maintained the gene of innovation, with pioneering work in the research and development of new drugs and treatments benefiting millions of patients. Since 2007, Novartis invest over 16% of its annual sales revenue to R&D. In 2014, the R&D investment reached USD 9.9 billion, and the company provided medical services to more than 1 billion people worldwide. In China, Novartis adheres to the notion of “commitment to China” and strive to have long-term investment and development in China. Since it entered China in 1987, Novartis is committed to improving the health and living standard of the Chinese people through innovative products and services. Meanwhile, Novartis actively cooperates with the Chinese government and medical institutions at all levels to support the Chinese government in creating a healthier China.

Novartis Having Top-Notch R&D in China

As the environment and lifestyle changes, the incidence rate of stomach and liver cancer continues to rise. The aging population in China is also suffering more from diseases like hypertension and cataracts.

Novartis has invested USD 1 billion to set up Novartis (China) Institutes for Biomedical Research in Shanghai, one of the three major R&D centres of the group. Not only is it involved in global projects, but also specifically works on cancer of high incidence in China (such as stomach cancer and liver cancer) and liver diseases (hepatitis and liver fibrosis, etc.) to meet the urgent medical needs of the patients. Meanwhile, Novartis (China) Institutes for Biomedical Research cooperates with Shanghai Institute of Materia Medica, Chinese Academy of Sciences and other key research institutes and biotechnology companies to boost the R&D capacity in China. In the past ten years, Novartis has been cooperating with Shanghai Institute of Materia Medica, Chinese Academy of Sciences to study the compounds extracted from natural products.

In addition, Novartis Pharmaceutical Development Centre in Changshu, Jiangsu is committed to the R&D of innovative drug process and analysis method as well as the production technology. This development centre supports early-stage clinical trials in Europe and the United States through toxicity research and recipe development in laboratory. It also develops safe, effective and environmentally-friendly production processes used in the mass production and optimizes the production process to improve the yield and quality of the product.

球项目，更针对中国高发的癌症（如胃癌和肝癌等）及肝病（肝炎和肝纤维化等），以满足病患迫切的医药需求。同时，诺华（中国）生物医学研究中心还与中国科学院上海药物研究所等重点科研院所和生物科技公司合作，支持中国医药自主研发能力的提升。过去十年间，诺华一直在与中国科学院上海药物研究所合作，从天然产物中提取化合物进行研究。

此外，诺华集团（中国）位于江苏常熟的化学研发中心则致力于创新性药物工艺与分析方法的研究及其生产技术的开发。这家研发中心通过实验室的毒理研究及配方开发支持欧洲及美国的早期临床试验，它还开发安全、高效、环保的生产工艺用于大规模生产，并优化生产工艺以提高产品产量及质量。

诺华支持中国的医疗卫生事业

诺华突破思维定式，坚持不懈寻找创新方法，以全面改善人们的医疗环境。通过新疆“健康快车”等项目，诺华支持政府在基层开展健康教育，帮助改善医疗基础设施，建立可持续发展的医疗专业能力。项目正式启动五年以来，已为150万人次学生及11万名成人进行了健康卫生知识培训，并有超过3000名医生、护士和医疗专业人员接受了传染病诊疗和慢性病的专业培训。

此外，诺华通过与政府及慈善机构合作，帮助经济困难患者获得急需的药品及医疗服务。自2003年以来，诺华与中华慈善总会合作，为超过3万名无法负担药品的癌症患者提供药物。诺华集团下属企业爱尔康（中国）为“中华健康快车”项目捐赠眼科手术设备，并为基层眼科医生进行专业培训，迄今已帮助超过16万名患者恢复视力。

同时，诺华始终积极加强与政府的研讨及沟通，致力于将诺华的医药健康行业专业经验与中国政府及行业分享，从而推动中国医药健康行业的提升。

诺华在中国执行最高专业标准

作为世界领先的医药健康公司，诺华致力于在公司运营的各个方面遵循最高专业准则，并推动行业标准的提升。不论身在世界何处，不论身肩何职，诺华的员工都充分领会一丝不苟地遵守最高专业准则的重要性。

诺华在中国的三大生产基地统一接受瑞士的技术和质量管理，始终以一流的质量标准提供高品质药物。诺华致力于培养最优秀的本土人才，诺华（中国）生物医学研究中心的200多名科学家有三分之二来自国内顶尖高校、医学研究中心和研究所，并通过“诺华中国大学”培训平台、与哈佛大学和北京大学等开展合作，保持员工领先的科研水平。诺华因此多次荣膺怡安翰威特（Aon Hewitt）、杰出雇主调研机构（Top Employers Institute）等颁发的“最佳雇主”、“中国杰出雇主”等荣誉。

同时，诺华积极为中国提供全球最佳的实践经验。通过论坛研讨和培训项目，诺华与中国医疗专业人士分享医药科学领域的最新发现与进展，推动中国医药行业整体标准的提升。

Novartis supports China's medical and health services

Novartis keeps thinking out of the box and perseveres to find innovative ways to improve the healthcare environment. Through initiatives like “Health Express” in Xinjiang, Novartis has supported the government in grass-roots health education, helped improve the healthcare infrastructure to establish sustainable medical capacity. In the five years that the initiative was launched, 1.5 million students and 110,000 adults received training on healthcare and hygiene, and more than 3,000 doctors, nurses and medical professionals took professional training on the diagnosis and treatment of epidemics and chronic diseases.

In addition, through cooperation with the government and charities, Novartis helps patients with financial difficulties to get urgently-needed medicines and medical services. Since 2003, Novartis has collaborated with China Charity Federation to provide drugs for more than 30,000 cancer patients who cannot afford them. Alcon (China), one of the subsidiaries of Novartis Group, donated eye surgery equipment to the “China Health Express” and provided professional training to ophthalmologists of the base level, who have helped more than 160,000 patients to recover vision.

Meanwhile, Novartis has been active in the discussion and communication with the government, committed to sharing our pharmaceutical and healthcare experience with the Chinese government and the whole sector, so as to improve China's whole medicine and healthcare industry.

Novartis implements highest professional standards in China

As the world's leading pharmaceutical and healthcare company, Novartis is committed to observing the highest professional standards in all aspects of company operations and promoting the upgrading of industry standards. Regardless of location and title, Novartis employees fully understand the importance of scrupulous compliance with the highest professional standards.

Novartis' three major production bases in China are managed centrally by Switzerland on technology and quality, and have always been providing high quality drugs to the top quality standards. Novartis is committed to developing the finest local talent. More than two thirds of the 200 scientists of Novartis (China) Institute of Biomedical Research come from top Chinese universities, medical research centres and institutes. Through the “Novartis China University” training platform, we cooperate with Harvard University and Peking University to keep our employees on the edge of scientific research. For this reason, Novartis has repeatedly won the honours of “Best Employers” and “China's Top Employers” from Aon Hewitt and Top Employers Institute.

Meanwhile, Novartis actively provides China with the best global practices. Through seminars and training programs, Novartis shares the latest discoveries and progress in medical science with Chinese medical professionals, facilitating the upgrade of the overall standards of China's medicine industry.

